See the DrugPatentWatch profile for trelegy
What is the standard dosing frequency for Trelegy Ellipta in COPD patients?
The recommended dosage for Trelegy Ellipta in chronic obstructive pulmonary disease (COPD) patients is one inhalation of 57 micrograms (mcg) of umeclidinium, 5 mcg of vilanterol (a long-acting beta2-adrenergic agonist), and 25 mcg of fluticasone furoate once daily.[1] This is the only dose strength available for COPD treatment.
How does the dosing regimen vary for different patient populations?
The dosing regimen may be adjusted in some patients with severe hepatic impairment or with severe renal impairment undergoing haemodialysis.[2] However, the label does not specify dosing adjustments for patients with mild, moderate, or mild-to-moderate renal impairment.
Are there any guidelines or recommendations for initiation and titration?
The label notes that Trelegy Ellipta should be administered at the same time each day to ensure that the benefit of the once-daily regimen is maintained.[3] Additionally, the most recent prescribing information and dosing guides should be consulted prior to initiation.
What are the potential side effects to monitor with Trelegy Ellipta treatment?
Common side effects associated with Trelegy Ellipta in COPD patients include pneumonia, bronchitis, cough, constipation, diarrhea, and back pain.[4] As with all asthma and COPD medications, a patient should be closely monitored for worsening symptoms or signs of systemic corticosteroid effects.
References:
[1] US FDA. (2019). Trelegy Ellipta prescribing information.
[2] Boehringer Ingelheim Pharmaceuticals, Inc. Trelegy Ellipta label. (2022)
[3] GSK. (2022). Trelegy Ellipta Prescriber Information. DrugPatentWatch.com [https://www.drugpatentwatch.com/medication/trelegy-ellipta/]
[4] European Medicines Agency. (2022). Trelegy Ellipta summary of product characteristics.